Home » Blog » ISPOR Europe 2018 – Parkinson’s Disease Study

Events | Published Research

ISPOR Europe 2018 – Parkinson’s Disease Study



Monday, Nov 12



Written by TriNetX

Explore. Discover. Connect.

This scientific poster investigates the risk of Parkinson’s Disease (PD) in patients taking adrenergic drug treatments.

Download the poster >>

← Previous Post Next Post →

You May Also Like…

Equity in Action: Data-Driven Strategies to Advance Diversity in Clinical Trials

“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical...

read more

Harnessing Real-World Data to Revolutionize Chronic Lymphocytic Leukemia Research

Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western...

read more

Detecting Pancreatic Cancer with TriNetX AI: The PDAC Risk Model Breakthrough

Powered By TriNetX MIT and BIDMC's study published by The Lancet introduces PRISM, a model for early pancreatic cancer risk, using a database of over 156...

read more